<div id="readability-page-1" class="page"><div><p>Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire remaining 99.5% stake in OrganOx Limited from a group of shareholders for $1.5 billion on August 23, 2025. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo. The transaction will be funded from cash on hand and borrowings.</p><p>  For the period ending December 31, 2024, OrganOx Limited reported total revenue of $69.14 million and EBIT of $9.01 million. As of December 31, 2024, OrganOx Limited reported total assets of $96.9 million and total common equity of $71.56 million.</p><p>  The transaction is subject to approval by regulatory board / committee. The transaction is expected to close in FY2025.</p><p>  Perella Weinberg Partners and Piper Sandler served as OrganOx?s financial advisors and Robbie McLaren, Ross McAloon, Charles Ruck, Elizabeth Richards, Betty Pang, Chad Jennings, Sean Finn, Maj Vaseghi, Kendall Burnett, Hector Armengod, Patrick English, Catherine Hein and Philipp Studt of Latham &amp; Watkins acted as legal counsel to OrganOx in this transaction.</p><p>Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders on October 30, 2025.</p></div></div>

4543

<p>泰爾默公司已完成對 OrganOx Limited 99.5% 股份的收購，交易金額為 15 億美元，使其成為全資子公司。該交易於 2025 年 10 月 30 日最終達成，資金來源為現金和借款。OrganOx 在截至 2024 年 12 月 31 日的年度報告中，總收入為 6914 萬美元，息税前利潤為 901 萬美元。此次交易由 Perella Weinberg Partners 和 Piper Sandler 提供顧問服務，法律顧問為 Latham & Watkins</p>

泰爾茂公司已完成從一組股東手中收購 OrganOx 有限公司剩餘 99.5% 股份的交易